Efficacy News and Research

RSS

New cancer research to be highlighted in AACR Annual Meeting 2013

The AACR Annual Meeting 2013 will bring more than 17,000 scientists, advocates, industry leaders and other professionals to Washington, D.C., for the latest in breakthrough cancer science.

12 Feb 2013

Community health workers can help individuals better manage their diabetes

Newly published results from a randomized controlled clinical trial in the Pacific U.S. territory of American Samoa add clear evidence for the emerging idea that community health workers can meaningfully improve type 2 diabetes care in medically underserved communities.

12 Feb 2013

Enzyme therapy slows progression of Batten disease in dogs

Batten disease is a rare, fatal genetic disorder that affects children. Currently, no effective treatment exists for the disease, which ultimately kills all who are affected. Dachshunds also suffer from Batten disease, and now researchers from the University of Missouri College of Veterinary Medicine and School of Medicine, in collaboration with BioMarin Pharmaceutical Inc., have developed a treatment for the disease that has significantly delayed the onset and progression of symptoms in the Dachshunds.

12 Feb 2013

Intra-arterial therapy no more effective than IV t-PA in treating acute ischemic stroke

A stroke survivor's chances of living independently after 90 days are not improved by the use of devices inserted into the artery to dissolve or remove a stroke-causing clot shortly after the onset of symptoms, according to a randomized controlled trial involving 656 patients.

11 Feb 2013

RNL BIO files new stem cell drug IND with KFDA to initiate phase II and III cerebral palsy trials

RNL BIO CO LTD (RNL) announced today the filing of an Investigational New Drug (IND) application with the Korean Food and Drug Administration (KFDA) to initiate clinical trials phase II and III assessing the company's RNL-Astrostem stem cell drug in patients with cerebral palsy.

11 Feb 2013

Sunitinib shows promise against metastatic renal cell carcinoma

Findings from clinical trial patients with metastatic renal cell carcinoma, a common kidney cancer, show they did not have accelerated tumor growth after treatment with sunitinib, in contrast to some study results in animals. Sunitinib is one of several drugs, either on the market or undergoing testing, that target blood vessel growth.

10 Feb 2013

Northwestern Medicine expert offers tips to battle seasonal affective disorder

Winter is in full force. With short days and less exposure to sunlight, everyone feels less energetic and more people are vulnerable to depression. Seasonal Affective Disorder (SAD), or winter depression, is a mood disorder related to seasonal variations of light. Symptoms start in late fall and oftentimes last until April or early spring. It affects between 10 to 20 percent of Americans, primarily younger adults and women.

10 Feb 2013

New insights on role of placebo in depression

A randomized controlled trial published in one of the last issue of Psychotherapy and Psychosomatics unravels new insights on the role of placebo in depression.

10 Feb 2013

Single gene therapy session can cure diabetes

Researchers from the Universitat Aut-noma de Barcelona (UAB), led by F-tima Bosch, have shown for the first time that it is possible to cure diabetes in large animals with a single session of gene therapy. As published this week in Diabetes, the principal journal for research on the disease, after a single gene therapy session, the dogs recover their health and no longer show symptoms of the disease.

10 Feb 2013

MMRF joins multiple myeloma community in celebrating FDA accelerated approval of Pomalyst

The Multiple Myeloma Research Foundation (MMRF) today joined the multiple myeloma community in celebrating the U.S. Food and Drug Administration's (FDA) decision to grant accelerated approval of Pomalyst (Celgene Corporation, pomalidomide) for the treatment of patients with relapsed and refractory multiple myeloma who no longer respond to currently available treatments.

10 Feb 2013

Shire commences ABH001 Phase 3 study in Epidermolysis Bullosa

Shire plc, today announced the initiation of a Phase 3 study designed to evaluate the efficacy and safety of ABH001, its dermal substitute therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a group of rare genetic skin disorders that begin to manifest at birth or early childhood and occur in approximately 19 per 1 million live births in the US.

10 Feb 2013

Neurocrine Biosciences fourth quarter net income increases to $9.5 million

Neurocrine Biosciences, Inc. today announced its financial results for the quarter and year ended December 31, 2012.

9 Feb 2013

Etanercept no better than prednisone for COPD exacerbations

Results from a randomized, double-blind, controlled trial suggest that the tumor necrosis factor α antagonist etanercept is no more effective than standard therapy with prednisone for the treatment of acute exacerbations in patients with chronic obstructive pulmonary disease.

8 Feb 2013